BIO lobbies lawmakers for new rules that expose biotech short sellers
Unidentified pedestrian views mobile device while walking past the New York Stock Exchange on July 3, 2017 Bloomberg via Getty
Long before the biotech IPO boom of 2013 and 2014, BIO had been an outspoken critic of short sellers. And now that the trade group’s rank-and-file has been swelled with public players, the group wants lawmakers to add a few new rules to bring the short crowd out into the light.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
